These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 447438)

  • 21. Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm.
    Debord J; Charmes JP; Marquet P; Merle L; Lachâtre G
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):24-7. PubMed ID: 9021438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetics of amikacin in subjects with normal renal function, in chronic renal failure and during hemodialysis].
    Oksenhendler G; Leroy A; Fillastre JP; Humbert G
    Nouv Presse Med; 1979 Oct; 8(42):3426-9. PubMed ID: 537888
    [No Abstract]   [Full Text] [Related]  

  • 24. Amikacin pharmacokinetics in morbidly obese patients.
    Bauer LA; Blouin RA; Griffen WO; Record KE; Bell RM
    Am J Hosp Pharm; 1980 Apr; 37(4):519-22. PubMed ID: 7377215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of amikacin in pony foals after a single intramuscular injection.
    Brown MP; Gronwall RR; Martinez DS; Beal C
    Am J Vet Res; 1986 Feb; 47(2):453-4. PubMed ID: 3954234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of peritoneal dialysis of the pharmacokinetics of amikacin.
    Matzke GR; Salem N; Bockbrader H; Blevins R
    Proc Clin Dial Transplant Forum; 1980; 10():302-4. PubMed ID: 7346850
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of amikacin in patients with renal insufficiency: relation of half-life and creatinine clearance.
    Pijck J; Hallynck T; Soep H; Baert L; Daneels R; Boelaert J
    J Infect Dis; 1976 Nov; 134 SUPPL():S331-41. PubMed ID: 993626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of the route of administration on the pharmacokinetics of amikacin.
    Lanao JM; Dominguez-Gil A; Tabernero JM; Corbacho L
    Eur J Clin Pharmacol; 1981; 19(5):367-70. PubMed ID: 7238565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amikacin concentrations in serum and blister fluid in healthy volunteers and in patients with renal impairment.
    Lanao JM; Navarro AS; Dominguez-Gil A; Tabernero JM; Rodriguez IC; Gonzalez Lopez A
    J Antimicrob Chemother; 1983 Nov; 12(5):481-8. PubMed ID: 6671925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period.
    Assael BM; Parini R; Rusconi F; Cavanna G
    Pediatr Res; 1982 Oct; 16(10):810-5. PubMed ID: 7145504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay.
    Plantier J; Forrey AW; O'Neill MA; Blair AD; Christopher TG; Cutler RE
    J Infect Dis; 1976 Nov; 134 SUPPL():S323-30. PubMed ID: 993625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of serum creatinine concentration and amikacin half-life.
    Levy J; Klastensky J
    J Clin Pharmacol; 1975 Oct; 15(10):705-7. PubMed ID: 1102570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis.
    Pechere JC; Dugal R; Pechere MM
    Eur J Drug Metab Pharmacokinet; 1979; 4(1):49-56. PubMed ID: 467467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical application of amikacin dosage based upon lean body mass in patients with different renal function.
    Wagenvoort JH; Fieren MW; Goessens WH; Michel MF
    Chemotherapy; 1984; 30(2):69-75. PubMed ID: 6697814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase of amikacin half-life during therapy in patients with renal insufficiency.
    Blaser J; Rüttimann S; Bhend H; Lüthy R
    Antimicrob Agents Chemother; 1983 Jun; 23(6):888-91. PubMed ID: 6614893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacology of amikacin and kanamycin.
    Kirby WM; Clarke JT; Libke RD; Regamey C
    J Infect Dis; 1976 Nov; 134 SUPPL():S312-5. PubMed ID: 993624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin.
    Bauer LA; Blouin RA
    Eur J Clin Pharmacol; 1983; 24(5):639-42. PubMed ID: 6873143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of cefamandole in rabbits with experimentally induced renal impairment.
    Campillo JA; Dominguez-Gil AA; Cepeda M; Dominguez-Gil A
    J Antibiot (Tokyo); 1980 Mar; 33(3):322-7. PubMed ID: 7380743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.